14 results about "Methoxyacetic acid" patented technology

The application relates to a concentration device for methoxyacetic acid preparation and relates to the technical field of methoxyacetic acid preparation, which comprises a concentration barrel, a spraying assembly, a collecting assembly, an evaporation assembly and a detection assembly. One side top of the concentration barrel is communicated with a liquid inlet pipe, the spraying assembly is arranged in the concentration barrel, the liquid inlet pipe is communicated with the spraying assembly, and the spraying assembly is used for spraying a solution needing to be concentrated into the concentration barrel. The collecting assembly is arranged at the bottom of the concentration barrel and is used for collecting the concentrated solution. A lead screw is fixedly arranged at the center of the bottom in the concentration barrel, the lead screw is a reciprocating lead screw, the lead screw is vertically arranged and coaxially arranged with the concentration barrel. A rotating block is spirally transmission-connected with the lead screw in the vertical direction. The evaporation assembly is used for contacting steam with the sprayed solution, so that the solvent in the solution is evaporated together. The detection assembly can assist in detecting the concentrated solution. The concentration device for methoxyacetic acid preparation can realize an efficient evaporation and concentration process.

Provided herein in some embodiments are pharmaceutical compositions comprising a prostacyclin (PGI2) receptor agonist selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1) and pharmaceutically acceptable salts, solvates, and hydrates thereof, as disclosed herein. In some embodiments the pharmaceutical compositions comprise a compound selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), and pharmaceutically acceptable salts, solvates, and hydrates thereof, in an amount equivalent to a therapeutically effective amount of Compound 1, the composition having a release rate by weight of the compound in an aqueous medium that is one or more of release rates (a), (b) and (c) as disclosed herein. The compositions of the present invention are useful in the treatment of PGI2 related disorders, such as those disclosed herein.

The present application discloses a method for preparing methyl ester compounds, which comprises subjecting a raw material of a carboxyl compound, methanol and / or dimethyl ether to an esterification reaction to obtain a methyl ester compound; wherein the general formula I of the carboxyl compound is R-CH2-COOH, and R is a methoxy group or a hydroxyl group; and the methyl ester compound comprises at least one of methyl methoxyacetate and methyl glycolate. The present application also discloses a method for preparing methyl glycolate, comprising the steps of: a) subjecting methylal to a carbonylation reaction with carbon monoxide to obtain methyl methoxyacetate; b) subjecting methyl methoxyacetate to a hydrolysis reaction with water to obtain methyl glycolate; and c) subjecting glycolic acid and methoxyacetic acid to an esterification reaction with methanol and dimethyl ether to obtain methyl glycolate. The above method can greatly simplify the separation process, save energy consumption, and provide a new synthetic route for the synthesis of methyl ester compounds, especially methyl glycolate.

The PMI foam comprises the following raw materials: methacrylonitrile, methacrylic acid, a toughening agent, a foaming agent, an initiator and a cross-linking agent. According to the PMI foam, the modified nitrile rubber is used as a toughening agent, so that the PMI foam has excellent toughening performance, and a mixture of ethyl methoxyacetate and methyl 3-methoxypropionate is used for dissolving the modified nitrile rubber when the PMI foam is prepared, so that the dissolving speed of the nitrile rubber can be greatly increased.

The invention belongs to the technical field of environmental protection, and relates to a preparation method of an ether-rich porous ionic liquid and desulfurization application of the ether-rich porous ionic liquid. The preparation method comprises the following steps: mixing 2-methylimidazole with a methanol solution of zinc nitrate hexahydrate, performing hydrothermal reaction, and performing centrifugal drying to obtain ZIF-8 white particles; the preparation method comprises the following steps: mixing tris (3, 6-dioxaheptyl) amine and methoxyacetic acid, reacting at normal temperature, and performing vacuum drying to obtain light yellow transparent ionic liquid [TMEA] [MOAC]; the preparation method comprises the following steps: mixing ZIF-8 with [TMEA] [MOAC], and carrying out ultrasonic oscillation and uniform dispersion at room temperature to obtain a faint yellow transparent solution ZIF-8 / [TMEA] [MOAC] porous ionic liquid. The porous ionic liquid disclosed by the invention has high specific surface area and high adsorbability of ZIF-8 and good flowability of the ionic liquid, a nano confinement space formed by an interface improves the synergistic interaction effect of multiple active sites, and the absorption performance and regeneration cycle of SOs under normal pressure are improved.

Provided herein in some embodiments are pharmaceutical compositions comprising a prostacyclin (PGI2) receptor agonist selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1) and pharmaceutically acceptable salts, solvates, and hydrates thereof, as disclosed herein. In some embodiments the pharmaceutical compositions comprise a compound selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), and pharmaceutically acceptable salts, solvates, and hydrates thereof, in an amount equivalent to a therapeutically effective amount of Compound 1, the composition having a release rate by weight of the compound in an aqueous medium that is one or more of release rates (a), (b) and (c) as disclosed herein. The compositions of the present invention are useful in the treatment of PGI2 related disorders, such as those disclosed herein.

Provided herein in some embodiments are pharmaceutical compositions comprising a prostacyclin (PGI2) receptor agonist selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1) and pharmaceutically acceptable salts, solvates, and hydrates thereof, as disclosed herein. In some embodiments the pharmaceutical compositions comprise a compound selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy) acetic acid (Compound 1), and pharmaceutically acceptable salts, solvates, and hydrates thereof, in an amount equivalent to a therapeutically effective amount of Compound 1, the composition having a release rate by weight of the compound in an aqueous medium that is one or more of release rates (a), (b) and (c) as disclosed herein. The compositions of the present invention are useful in the treatment of PGI2 related disorders, such as those disclosed herein.

The application relates to a PMI foam which comprises the following raw materials: methacrylonitrile, methacrylic acid, a toughening agent, a foaming agent, an initiator and a crosslinking agent. The PMI foam described in the application has excellent toughening performance by using modified nitrile rubber as the toughening agent, and the dissolution speed of the nitrile rubber can be greatly improved by using a mixture of ethyl-methoxyacetate and methyl-3-methoxypropionate to dissolve the modified nitrile rubber when the PMI foam is prepared.

The invention discloses a solid-phase synthesis method of acetyl hexapeptide-8, which comprises the following steps: by taking RINK AMIDE-AM resin as a carrier, gradually coupling Fmoc-Arg (HCl)-OH, Fmoc-Arg (HCl)-OH, Fmoc-Gln-OH, Fmoc-Met-OH, Fmoc-Glu (OtBu)-OH and Fmoc-Glu (OtBu)-OH amino acids, carrying out deprotection, acetylation and cleavage reaction to prepare crude peptide, and finally purifying to obtain a target product. According to the method, a minimum amino acid protection strategy is adopted, a cracking system is optimized, a modified silica gel chromatographic filler is combined, and a modifier comprises N-(benzo [D] thiazole-2-yl methyl) acrylamide and methyl 2-acrylamido-2-methoxy acetate, so that the column chromatography purification efficiency is improved, the product purity is high, the yield is high, the operation is simple, and the method is suitable for large-scale production.

Provided herein in some embodiments are pharmaceutical compositions comprising a prostacyclin (PGI2) receptor agonist selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1) and pharmaceutically acceptable salts, solvates, and hydrates thereof, as disclosed herein. In some embodiments the pharmaceutical compositions comprise a compound selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), and pharmaceutically acceptable salts, solvates, and hydrates thereof, in an amount equivalent to a therapeutically effective amount of Compound 1, the composition having a release rate by weight of the compound in an aqueous medium that is one or more of release rates (a), (b) and (c) as disclosed herein. The compositions of the present invention are useful in the treatment of PGI2 related disorders, such as those disclosed herein.

The invention relates to a preparation method of apixaban, which comprises the following steps: carrying out aldol condensation on ethyl methoxyacetate serving as a raw material and ethyl pyruvate to obtain an intermediate II, carrying out alkylation reaction on the intermediate II and 1, 2-dichloroethane to obtain an intermediate III, carrying out pyrazole synthesis reaction on the intermediate III and 4-methoxyphenylhydrazine to obtain an intermediate IV, carrying out alkylation reaction on the intermediate IV and 4-nitroaniline to obtain an intermediate V, and carrying out recrystallization on the intermediate V to obtain the apixaban. The preparation method comprises the following steps: carrying out ester group hydrolysis to prepare an intermediate VI, carrying out molecular lactamization in the presence of a condensing agent to prepare an intermediate VII, carrying out nitro reduction to prepare an intermediate VIII, carrying out amidation on the intermediate VIII and 5-bromovaleryl chloride under the action of an acid-binding agent, further carrying out an intramolecular alkylation reaction under the action of a strong alkali to prepare an intermediate IX, adding tert-butyl hydroperoxide and ammonia water, and carrying out a reaction under the action of a strong alkali to prepare the intermediate IX. Under the catalysis of iodine, carrying out oxidation amidation to prepare apixaban; the method has the advantages of cheap and easily available raw materials, easy realization of industrialization, high product purity, no dangerous process, simple equipment, novel route and short synthesis route.

The invention provides a synthetic preparation process of methoxyacetic acid, which comprises the following steps: mixing ethylene glycol monomethyl ether, a water solvent, an auxiliary agent and a platinum-loaded carbon catalyst in a reactor to form a reaction mixture; introducing inert gas into the reactor to replace air in the reactor; the method comprises the following steps: heating a reactor to 80-90 DEG C under a stirring condition, introducing oxidant gas, maintaining the reaction pressure at 1.0-1.5 bar, and reacting for 3-4 hours to oxidize ethylene glycol monomethyl ether to generate methoxyacetic acid; after the reaction is finished, cooling reaction liquid, and filtering and separating the platinum-loaded carbon catalyst to obtain filtrate; adding an acidifying reagent into the filtrate, and adjusting the pH value to 1.0-4.5; separating methoxyacetic acid from the acidified liquid by a crystallization method; and carrying out reduced pressure distillation or drying to obtain purified methoxyacetic acid.

The application discloses a solid-phase synthesis method of acetyl hexapeptide-8. RINK AMIDE-AM resin is used as a carrier, Fmoc-Arg(HCl)-OH, Fmoc-Arg(HCl)-OH, Fmoc-Gln-OH, Fmoc-Met-OH, Fmoc-Glu(OtBu)-OH and Fmoc-Glu(OtBu)-OH amino acids are coupled step by step, crude peptides are prepared through deprotection, acetylation and cleavage reaction, and finally the target product is obtained through purification. The method adopts a minimum amino acid protection strategy, optimizes a cleavage system, and combines modified silica gel chromatography packing materials. The modifiers include N-(benzo[D]thiazole-2-ylmethyl) acrylamide and methyl 2-acrylamido-2-methoxyacetate, so that the column chromatography purification efficiency is improved, the product has high purity and high yield, and the operation is simple and suitable for scale-up production.

The present invention relates to a herbicidal composition comprising (A) an herbicidal amount of a compound of Formula (I) (I) wherein G is selected from the group consisting of hydrogen, -C(O)CH3 and -C(O)OCH3;and (B) at least one herbicide, or an ester or salt thereof acceptable from an agrochemical point of view, selected from the group consisting of icafolin (B1) (or icafolin-methyl (B1a)), benquitrione (B2), broclozone (B3), butachlor (B4), clomazone (B5), cyclopyranyl (B6), fluchloraminopyr (B7) [or fluchloraminopyr-tefuryl pyraquinate (B9), (B7a)], fluphenoxymacyl (B8), 2-[2-[2-bromo-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy]phenoxy]-2-methyl methoxy acetate (B10), 6-chloro-4-(2,7-dimethyl-1-naphthyl)-5-hydroxy-2-methylpyridazin-3-one (B11), 3-[2-chloro 5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2H)pyrimidinyl]-4-fluorophenyl]-3a,4,5,6-tetrahydro-6-methyl-6aH cyclopent[d]isoxazol-6a-methylcarboxylate (B12), 2-[1 [[2-(4-chlorophenoxy)propoxy]imino]butyl]-5-[2 (ethylthio)propyl]-3-hydroxy-2-cyclohexen-1-one (B13), 2-[(2 2 5 10 15 20 25 bromo-6-fluorophenyl)methoxy]-4-isopropyl-1-methyl-7 oxabicyclo[2.2.1]heptane (B14) and diflufenican (B15).;